Literature DB >> 3356795

Use of cryopreserved normal peripheral blood lymphocytes for isolation of human immunodeficiency virus from seropositive men.

R Balachandran1, P Thampatty, C Rinaldo, P Gupta.   

Abstract

The possibility was investigated of using frozen stocks of phytohemagglutinin (PHA)-stimulated normal human peripheral blood lymphocytes (PBL) in cocultivation with human immunodeficiency virus (HIV)-infected lymphocytes for the isolation of HIV. Fresh and cryopreserved PBL from eight healthy volunteers were compared for their susceptibility to HIV infection in vitro. Fresh lymphocytes, as well as lymphocytes that were stimulated with PHA before or after cryopreservation, displayed comparable susceptibilities to HIV infection in vitro. In addition, HIV was recovered in all cases when lymphocytes stimulated with PHA before or after cryopreservation were cocultured in parallel with PBL from 15 patients with acquired immune deficiency syndrome. However, the cryopreserved PBL were less efficient in isolating HIV from asymptomatic men.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3356795      PMCID: PMC266343          DOI: 10.1128/jcm.26.3.595-597.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  Gene transfer, expression, and molecular cloning of the human transferrin receptor gene.

Authors:  L C Kühn; A McClelland; F H Ruddle
Journal:  Cell       Date:  1984-05       Impact factor: 41.582

2.  Lymphadenopathy associated virus infection of a blood donor--recipient pair with acquired immunodeficiency syndrome.

Authors:  P M Feorino; V S Kalyanaraman; H W Haverkos; C D Cabradilla; D T Warfield; H W Jaffe; A K Harrison; M S Gottlieb; D Goldfinger; J C Chermann
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

3.  Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.

Authors:  W J Leonard; J M Depper; G R Crabtree; S Rudikoff; J Pumphrey; R J Robb; M Krönke; P B Svetlik; N J Peffer; T A Waldmann
Journal:  Nature       Date:  1984 Oct 18-24       Impact factor: 49.962

4.  HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS.

Authors:  J E Groopman; S Z Salahuddin; M G Sarngadharan; P D Markham; M Gonda; A Sliski; R C Gallo
Journal:  Science       Date:  1984-10-26       Impact factor: 47.728

5.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

6.  Functional integrity of cryopreserved human monocytes.

Authors:  R S Weiner; S J Normann
Journal:  J Natl Cancer Inst       Date:  1981-02       Impact factor: 13.506

7.  Detection of human immunodeficiency virus by reverse transcriptase assay, antigen capture assay, and radioimmunoassay.

Authors:  P Gupta; R Balachandran; K Grovit; D Webster; C Rinaldo
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

8.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  7 in total

1.  Immunomagnetic selection of purified monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation.

Authors:  J W Sleasman; B H Leon; L F Aleixo; M Rojas; M M Goodenow
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

2.  Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.

Authors:  Lisa M Demeter; Ronald J Bosch; Robert W Coombs; Susan Fiscus; James Bremer; Victoria A Johnson; Alejo Erice; J Brooks Jackson; Stephen A Spector; Kathleen M Squires; Margaret A Fischl; Michael D Hughes; Scott M Hammer
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

3.  Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.

Authors:  F B Hollinger; J W Bremer; L E Myers; J W Gold; L McQuay
Journal:  J Clin Microbiol       Date:  1992-07       Impact factor: 5.948

4.  Cell-to-cell transmission of human immunodeficiency virus type 1 in the presence of azidothymidine and neutralizing antibody.

Authors:  P Gupta; R Balachandran; M Ho; A Enrico; C Rinaldo
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Prospective multicenter study on isolation of human immunodeficiency virus type 1 from homosexual men after seroconversion.

Authors:  P Gupta; H Farzadegan; D Imagawa; M Lee; L Kingsley; S Zhou; J Armstrong; C Rinaldo
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

6.  Effective use of frozen donor peripheral blood mononuclear cells for human immunodeficiency virus type 1 isolation from vertically infected pediatric patients.

Authors:  M O Paul; S Tetali; S Pahwa
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

Review 7.  The diagnosis of human immunodeficiency virus infection: progress in less than five years.

Authors:  F J Michalski
Journal:  Yale J Biol Med       Date:  1989 Mar-Apr
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.